Huperzine A is a substance purified from a plant called Chinese club moss. It is commonly used as a dietary supplement to improve memory and mental function in people with Alzheimer's disease, other types of dementia, age-related memory loss, and other conditions. According to Gen Consulting Company, global huperzine A market is expected to expand at a CAGR of 6.68% over the forecast period i.e. 2020-2026. Growing potential for huperzine A in therapies for Alzheimer's disease is the chief contributor for the growth of the market.
Key players profiled in this report are:
- Cisen Pharmaceutical Co., Ltd.
- Beijing Hwells Pharmaceutical Co., Ltd.
- Shanghai Fudan Forward Pharmaceutical Co., Ltd.
Other companies in the market include Debiopharm Group, XYMOGEN, Inc., Xel Pharmaceuticals, Inc., Hainan Lingkang Pharmaceutical Co., Ltd., Simcere Pharmaceutical Group, Henan Taloph Pharmaceutical Stock Co., Ningbo Liwah Pharmaceutical Co., Ltd., Ningbo Green-Health Pharma-ceutical Co., Ltd, Shenzhen Zhonglian Pharmaceutical Co., Ltd., Wanbang Pharmaceutical Group Co., Ltd., Zhejiang Judu Pharmaceutical Group Co.,Ltd., Zhejiang Zhenyuan Pharmaceutical Co., Ltd., Yaoyou Chongqing Pharmaceutical Co., Ltd., etc.
Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth rate of huperzine A in these regions, from 2020 to 2026, covering North America, Europe, Asia-Pacific and RoW. China reckoned as the most significant regional market and is anticipated to develop at a 6.8% CAGR from 2020 to 2026. Growing incidence of the Alzheimer's and worldwide increase in the geriatric population are driving the China's Alzheimer's therapeutics market.
The base year of the study is 2019, and forecasts run up to 2026.
Research Objective
- To analyze and forecast the market size of global huperzine A market.
- To classify and forecast global huperzine A market based on region.
- To identify drivers and challenges for global huperzine A market.
- To examine competitive developments such as expansions, mergers & acquisitions, etc., in global huperzine A market.
- To identify and analyze the profile of leading players operating in global huperzine A market.
The report is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities. Key target audience are:
- Manufacturers of huperzine A
- Raw material suppliers
- Market research and consulting firms
- Government bodies such as regulating authorities and policy makers
- Organizations, forums and alliances related to huperzine A
1. Summary 2. Objectives of The Study 3. Scope of the Report 3.1 Markets Covered 3.2 Years Considered for The Report 3.3 Currency 4. Market Research Methodology 5. Introduction 5.1 Overview 5.2 Natural Huperzine A and Synthetic Huperzine A 5.3 Value Chain 5.4 Mechanisms of Action 5.5 Product Form (Tablet, Capsule, Injection, etc.) 6. Product Pipeline 6.1 Wagelan/瓦格兰 6.2 Yinuo/忆诺 6.3 Shuangyiping/双益平 6.4 DEBIO 9902 6.5 MemorAll™ 6.6 XEL 001HP 7. Rule, Regulation and Policy 7.1 Regulation and Policy in China 7.2 Regulation and Policy in Other Countries 8. Market Landscape 8.1 Market Size and Forecast 8.2 Market by Company 9. Alzheimer's Disease 9.1 The Basics of Alzheimer's Disease 9.2 Stages of Alzheimer's Disease 9.3 Therapies for Alzheimer's Disease 9.4 Huperzine A in the Treatment of Alzheimer's Disease 10. Huperzine A Market by Region 10.1 Huperzine A Market in North America 10.2 Huperzine A Market in Europe 10.3 Huperzine A Market in China 11. Drivers & Challenges 11.1 Market Growth Drivers 11.2 Market Challenges 11.3 Market Trends 12. Patents Analysis 12.1 Global Huperzine A Patents Analysis 12.2 China's Huperzine A Patents Analysis 13. Key Vendor Analysis 13.1 Debiopharm Group 13.2 Cisen Pharmaceutical Co., Ltd. 13.3 Beijing Hwells Pharmaceutical Co., Ltd. 13.4 XYMOGEN, Inc. 13.5 Xel Pharmaceuticals, Inc. 13.6 Hainan Lingkang Pharmaceutical Co., Ltd. 13.7 Simcere Pharmaceutical Group 13.8 Henan Taloph Pharmaceutical Stock Co. 13.9 Ningbo Liwah Pharmaceutical Co., Ltd. 13.10 Ningbo Green-Health Pharma-ceutical Co., Ltd 13.11 Shanghai Fudan Forward Pharmaceutical Co., Ltd. 13.12 Shenzhen Zhonglian Pharmaceutical Co., Ltd. 13.13 Wanbang Pharmaceutical Group Co., Ltd. 13.14 Zhejiang Judu Pharmaceutical Group Co.,Ltd. 13.15 Zhejiang Zhenyuan Pharmaceutical Co., Ltd. 13.16 Yaoyou Chongqing Pharmaceutical Co., Ltd. 14. Attachment DISCLAIMER ABOUT GEN CONSULTING COMPANY
| Price : US$ 3,500 | Date : Apr 2023 |
| Category : Chemicals and Materials | Pages : 143 |
| Price : US$ 3,000 | Date : Jan 2022 |
| Category : Chemicals and Materials | Pages : 104 |
| Price : US$ 2,890 | Date : Mar 2021 |
| Category : Chemicals and Materials | Pages : 122 |
| Price : US$ 4,000 | Date : Apr 2019 |
| Category : Chemicals and Materials | Pages : 145 |
We are happy to help! Call or write to us
Request Sample 
Request Discount 
Inquire Before Buy
